Castle Biosciences, Inc.2025财年第一财季实现净利润-25.85百万美元，同比减少921.74%

市场透视2025-05-11

5月11日，Castle Biosciences, Inc.（CSTL.US）公布财报，公告显示公司2025财年第一财季净利润为-25.85百万美元，同比减少921.74%；其中营业收入为87.99百万美元，同比增加20.58%，每股基本收益为-0.90美元。从资产负债表来看，Castle Biosciences, Inc.（CSTL.US）总负债61.41百万美元，其中短期债务2.55百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2534779429?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-11 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2534779429","market":"us","top_or_hot":-1,"title":"Castle Biosciences, Inc.2025财年第一财季实现净利润-25.85百万美元，同比减少921.74%","media":"市场透视","content":"<div>\n<p>5月11日，Castle Biosciences, Inc.（CSTL.US）公布财报，公告显示公司2025财年第一财季净利润为-25.85百万美元，同比减少921.74%；其中营业收入为87.99百万美元，同比增加20.58%，每股基本收益为-0.90美元。从资产负债表来看，Castle Biosciences, Inc.（CSTL.US）总负债61.41百万美元，其中短期债务2.55百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250511000443a479615e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Castle Biosciences, Inc.2025财年第一财季实现净利润-25.85百万美元，同比减少921.74%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCastle Biosciences, Inc.2025财年第一财季实现净利润-25.85百万美元，同比减少921.74%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-11 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250511000443a479615e&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月11日，Castle Biosciences, Inc.（CSTL.US）公布财报，公告显示公司2025财年第一财季净利润为-25.85百万美元，同比减少921.74%；其中营业收入为87.99百万美元，同比增加20.58%，每股基本收益为-0.90美元。从资产负债表来看，Castle Biosciences, Inc.（CSTL.US）总负债61.41百万美元，其中短期债务2.55百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250511000443a479615e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSTL","symbol_name":"Castle Biosciences, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250511000443a479615e&s=b","article_id":"2534779429","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250511000443a479615e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2534779429","pubTimestamp":1746892891,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月11日，Castle Biosciences, Inc.公布财报，公告显示公司2025财年第一财季净利润为-25.85百万美元，同比减少921.74%；其中营业收入为87.99百万美元，同比增加20.58%，每股基本收益为-0.90美元。从资产负债表来看，Castle Biosciences, Inc.总负债61.41百万美元，其中短期债务2.55百万美元，资产负债比为0.09，流动比率为0.10。机构评级：截至2025年5月11日，当前有9家机构对Castle Biosciences, Inc.目标价做出预测，其中目标均价为36.33美元，其中最低目标价为30.00美元，最高目标价为44.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"CSTL":"Castle Biosciences, Inc."},"translate_title":"Castle Biosciences, Inc. achieved net profit of-25.85 million US dollars in the first fiscal quarter of fiscal year 2025, a year-on-year decrease of 921.74%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSTL":1},"content_text":"5月11日，Castle Biosciences, Inc.（CSTL.US）公布财报，公告显示公司2025财年第一财季净利润为-25.85百万美元，同比减少921.74%；其中营业收入为87.99百万美元，同比增加20.58%，每股基本收益为-0.90美元。从资产负债表来看，Castle Biosciences, Inc.（CSTL.US）总负债61.41百万美元，其中短期债务2.55百万美元，资产负债比为0.09，流动比率为0.10。机构评级：截至2025年5月11日，当前有9家机构对Castle Biosciences, Inc.目标价做出预测，其中目标均价为36.33美元，其中最低目标价为30.00美元，最高目标价为44.00美元。公司简介：Castle Biosciences Inc是一家商业阶段的皮肤癌公司。它致力于为医生及其患者提供个性化的、可在临床上应用的基因组信息，以做出更准确的治疗决策。 该公司的产品组合包括皮肤黑素瘤、DecisionDx-黑色素瘤，DecisionDx-CMSeq、DecisionDx-PRAME等。该公司的测试组合包括帮助临床医生诊断和治疗皮肤病学、胃肠病学和眼科学领域的癌症或癌前病变的测试产品，以及用于指导患有抑郁症、焦虑症和其他精神健康状况的患者进行最佳药物治疗的药物基因组学(PGx)测试。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2534779429","isCrawlerRequest":true}